drugset / Trial / NCT07523334

Impact of Esketamine on Delayed Neurocognitive Recovery in Older Patients

NCT07523334

RandomizedParallel-groupQuadruple-blindPrevention

Summary

Esketamine is frequently used during the perioperative period for supplemental analgesia. Small sample size trials showed that subanesthetic dose esketamine may decrease postoperative neurocognitive complications. However, conflicting results exist and optimal dose of esketamine remains to be determined. This dose-exploring pilot trial is designed to evaluate the safety and efficacy of three different perioperative esketamine dosing regimens in older patients undergoing major non-cardiac surgery. The primary purpose is to explore the optimal dosing strategy that produce maximal neurocognitive benefits with minimal adverse neuropsychiatric symptoms.

Timeline

Start
2026-04
Primary completion
2026-12
Completion
2026-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Esketamine Other / unclassified 0.05 mg/kg Intravenous
Subject Esketamine Other / unclassified 0.1 mg/kg Intravenous
Subject Esketamine Other / unclassified 0.15 mg/kg Intravenous

Indications